Takeda — Primary IgA Nephropathy
Cutting-Edge Kidney Trials on the Space Coast
Phase 3 · Double-blind
Combination with stable background therapy · Reduction of UACR + IgA Nephropathy progression
Target audience: IgAN patients.
Potentially slow or stop progression of your IgAN with a new treatment option.
Screening within 1 week · Most trials compensated · Space Coast location
Meet Your Research Team
| Danielle Hurlbert - Research Coordinator — Space Coast Pod |
| Email dhurlbert@panoramichealth.com |
| Phone Office 321-768-3655 ext. 6024 |
| Hours Mon–Thu 8:00 AM – 5:00 PM · Fri 8:00 AM – 12:00 PM |
| Location 111 E. Hibiscus Blvd Melbourne, FL 32901 |
| Nationally recognized research center |